Replies to post #222566 on Biotech Values

[Trend-Setter]

"The treatment appeared to be safe and well tolerated and the study confirmed activation of the TLR9 pathway. AZD1419 is an investigational TLR9 agonist developed by Dynavax in collaboration with AstraZeneca. The proposed mechanism of action of AZD1419 is distinct from that of the other TLR9 agonists being developed by Dynavax for immuno-oncology and vaccine applications. AstraZeneca will now review the full data before deciding on the next steps for the AZD1419 program. The data will be presented at a future medical meeting."

Maybe its not over yet? Up to AZN now.